Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTTION systematic review

Jennifer S. Gewandter, Christopher H. Gibbons, Marta Campagnolo, Joonho Lee, Jenna Chaudari, Nam Ward, Laurie Burke, Guido Cavaletti, David N. Herrmann, Justin Charles McArthur, James W. Russell, A. Gordon Smith, Shannon M. Smith, Dennis C. Turk, Robert H. Dworkin, Roy Freeman

Research output: Contribution to journalReview article

Abstract

Distal symmetrical axonal polyneuropathy (DSP) is due to injury to peripheral sensory, motor, and autonomic nerve fibers, resulting in distal predominant sensory loss, pain, and gait instability. DSP occurs as a complication of multiple medical conditions including diabetes or HIV, or following exposure to various toxins such as chemotherapy. It affects at least 10% of the United States population. Few treatments for DSP are approved by regulatory agencies. Reliable and responsive outcome measures are integral to developing new DSP treatments. Multiple clinician-rated measures that incorporate neuropathy signs exist, however, it is not clear which of these measures performs best for various DSP phenotypes. This systematic review summarizes the content of 18 published measures of DSP identified using PubMed and from personal archives of the authors. The relative percentage of scoring dedicated to motor, reflex, large and small fiber sensory, and autonomic domains varied considerably among measures. The most common neurologic examination items included in the scales were (1) vibration perception (n = 18, 100%), (2) reflexes (n = 16, 89%), (3) pinprick perception (n = 14, 78%), (4) muscle strength (n = 11, 61%), (5) touch-pressure perception (n = 9, 50%), and (6) joint position perception (n = 8, 44%). This review can be used to inform decisions regarding which of the available clinician-rated sign outcome measures would be most appropriate for use in a particular DSP population, based on the domains most affected by that neuropathy or on the domains most likely to be affected by a particular experimental therapy.

Original languageEnglish (US)
Pages (from-to)346-360
Number of pages15
JournalNeurology
Volume93
Issue number8
DOIs
StatePublished - Aug 20 2019

Fingerprint

Polyneuropathies
Reflex
Touch Perception
Outcome Assessment (Health Care)
Autonomic Pathways
Investigational Therapies
Neurologic Examination
Muscle Strength
Vibration
Gait
Nerve Fibers
PubMed
Population
Joints
HIV
Phenotype
Pressure
Drug Therapy
Pain
Wounds and Injuries

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Gewandter, J. S., Gibbons, C. H., Campagnolo, M., Lee, J., Chaudari, J., Ward, N., ... Freeman, R. (2019). Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTTION systematic review. Neurology, 93(8), 346-360. https://doi.org/10.1212/WNL.0000000000007974

Clinician-rated measures for distal symmetrical axonal polyneuropathy : ACTTION systematic review. / Gewandter, Jennifer S.; Gibbons, Christopher H.; Campagnolo, Marta; Lee, Joonho; Chaudari, Jenna; Ward, Nam; Burke, Laurie; Cavaletti, Guido; Herrmann, David N.; McArthur, Justin Charles; Russell, James W.; Smith, A. Gordon; Smith, Shannon M.; Turk, Dennis C.; Dworkin, Robert H.; Freeman, Roy.

In: Neurology, Vol. 93, No. 8, 20.08.2019, p. 346-360.

Research output: Contribution to journalReview article

Gewandter, JS, Gibbons, CH, Campagnolo, M, Lee, J, Chaudari, J, Ward, N, Burke, L, Cavaletti, G, Herrmann, DN, McArthur, JC, Russell, JW, Smith, AG, Smith, SM, Turk, DC, Dworkin, RH & Freeman, R 2019, 'Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTTION systematic review', Neurology, vol. 93, no. 8, pp. 346-360. https://doi.org/10.1212/WNL.0000000000007974
Gewandter JS, Gibbons CH, Campagnolo M, Lee J, Chaudari J, Ward N et al. Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTTION systematic review. Neurology. 2019 Aug 20;93(8):346-360. https://doi.org/10.1212/WNL.0000000000007974
Gewandter, Jennifer S. ; Gibbons, Christopher H. ; Campagnolo, Marta ; Lee, Joonho ; Chaudari, Jenna ; Ward, Nam ; Burke, Laurie ; Cavaletti, Guido ; Herrmann, David N. ; McArthur, Justin Charles ; Russell, James W. ; Smith, A. Gordon ; Smith, Shannon M. ; Turk, Dennis C. ; Dworkin, Robert H. ; Freeman, Roy. / Clinician-rated measures for distal symmetrical axonal polyneuropathy : ACTTION systematic review. In: Neurology. 2019 ; Vol. 93, No. 8. pp. 346-360.
@article{99a54f74d9584ae0ba19bfd3814c1794,
title = "Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTTION systematic review",
abstract = "Distal symmetrical axonal polyneuropathy (DSP) is due to injury to peripheral sensory, motor, and autonomic nerve fibers, resulting in distal predominant sensory loss, pain, and gait instability. DSP occurs as a complication of multiple medical conditions including diabetes or HIV, or following exposure to various toxins such as chemotherapy. It affects at least 10{\%} of the United States population. Few treatments for DSP are approved by regulatory agencies. Reliable and responsive outcome measures are integral to developing new DSP treatments. Multiple clinician-rated measures that incorporate neuropathy signs exist, however, it is not clear which of these measures performs best for various DSP phenotypes. This systematic review summarizes the content of 18 published measures of DSP identified using PubMed and from personal archives of the authors. The relative percentage of scoring dedicated to motor, reflex, large and small fiber sensory, and autonomic domains varied considerably among measures. The most common neurologic examination items included in the scales were (1) vibration perception (n = 18, 100{\%}), (2) reflexes (n = 16, 89{\%}), (3) pinprick perception (n = 14, 78{\%}), (4) muscle strength (n = 11, 61{\%}), (5) touch-pressure perception (n = 9, 50{\%}), and (6) joint position perception (n = 8, 44{\%}). This review can be used to inform decisions regarding which of the available clinician-rated sign outcome measures would be most appropriate for use in a particular DSP population, based on the domains most affected by that neuropathy or on the domains most likely to be affected by a particular experimental therapy.",
author = "Gewandter, {Jennifer S.} and Gibbons, {Christopher H.} and Marta Campagnolo and Joonho Lee and Jenna Chaudari and Nam Ward and Laurie Burke and Guido Cavaletti and Herrmann, {David N.} and McArthur, {Justin Charles} and Russell, {James W.} and Smith, {A. Gordon} and Smith, {Shannon M.} and Turk, {Dennis C.} and Dworkin, {Robert H.} and Roy Freeman",
year = "2019",
month = "8",
day = "20",
doi = "10.1212/WNL.0000000000007974",
language = "English (US)",
volume = "93",
pages = "346--360",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Clinician-rated measures for distal symmetrical axonal polyneuropathy

T2 - ACTTION systematic review

AU - Gewandter, Jennifer S.

AU - Gibbons, Christopher H.

AU - Campagnolo, Marta

AU - Lee, Joonho

AU - Chaudari, Jenna

AU - Ward, Nam

AU - Burke, Laurie

AU - Cavaletti, Guido

AU - Herrmann, David N.

AU - McArthur, Justin Charles

AU - Russell, James W.

AU - Smith, A. Gordon

AU - Smith, Shannon M.

AU - Turk, Dennis C.

AU - Dworkin, Robert H.

AU - Freeman, Roy

PY - 2019/8/20

Y1 - 2019/8/20

N2 - Distal symmetrical axonal polyneuropathy (DSP) is due to injury to peripheral sensory, motor, and autonomic nerve fibers, resulting in distal predominant sensory loss, pain, and gait instability. DSP occurs as a complication of multiple medical conditions including diabetes or HIV, or following exposure to various toxins such as chemotherapy. It affects at least 10% of the United States population. Few treatments for DSP are approved by regulatory agencies. Reliable and responsive outcome measures are integral to developing new DSP treatments. Multiple clinician-rated measures that incorporate neuropathy signs exist, however, it is not clear which of these measures performs best for various DSP phenotypes. This systematic review summarizes the content of 18 published measures of DSP identified using PubMed and from personal archives of the authors. The relative percentage of scoring dedicated to motor, reflex, large and small fiber sensory, and autonomic domains varied considerably among measures. The most common neurologic examination items included in the scales were (1) vibration perception (n = 18, 100%), (2) reflexes (n = 16, 89%), (3) pinprick perception (n = 14, 78%), (4) muscle strength (n = 11, 61%), (5) touch-pressure perception (n = 9, 50%), and (6) joint position perception (n = 8, 44%). This review can be used to inform decisions regarding which of the available clinician-rated sign outcome measures would be most appropriate for use in a particular DSP population, based on the domains most affected by that neuropathy or on the domains most likely to be affected by a particular experimental therapy.

AB - Distal symmetrical axonal polyneuropathy (DSP) is due to injury to peripheral sensory, motor, and autonomic nerve fibers, resulting in distal predominant sensory loss, pain, and gait instability. DSP occurs as a complication of multiple medical conditions including diabetes or HIV, or following exposure to various toxins such as chemotherapy. It affects at least 10% of the United States population. Few treatments for DSP are approved by regulatory agencies. Reliable and responsive outcome measures are integral to developing new DSP treatments. Multiple clinician-rated measures that incorporate neuropathy signs exist, however, it is not clear which of these measures performs best for various DSP phenotypes. This systematic review summarizes the content of 18 published measures of DSP identified using PubMed and from personal archives of the authors. The relative percentage of scoring dedicated to motor, reflex, large and small fiber sensory, and autonomic domains varied considerably among measures. The most common neurologic examination items included in the scales were (1) vibration perception (n = 18, 100%), (2) reflexes (n = 16, 89%), (3) pinprick perception (n = 14, 78%), (4) muscle strength (n = 11, 61%), (5) touch-pressure perception (n = 9, 50%), and (6) joint position perception (n = 8, 44%). This review can be used to inform decisions regarding which of the available clinician-rated sign outcome measures would be most appropriate for use in a particular DSP population, based on the domains most affected by that neuropathy or on the domains most likely to be affected by a particular experimental therapy.

UR - http://www.scopus.com/inward/record.url?scp=85071703886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071703886&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000007974

DO - 10.1212/WNL.0000000000007974

M3 - Review article

C2 - 31320471

AN - SCOPUS:85071703886

VL - 93

SP - 346

EP - 360

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -